Saakshi Khattri, MD

Targeting Disease Modification for Psoriasis and Psoriatic Arthritis

17:30 - Defining Minimal Disease Activity

35:35 - Preventing Progression from PSO to PSA

Videos

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

0:00 Overlap of PsO and PsA
4:00 Detecting Early PsA
13:20 Treatments for PsA
18:00 Defining Minimal Disease Activity
24:50 Biologics for PsA
31:00 Efficacy of IL-17i and IL-23i
37:00 Preventing Progression from PsO to PsA

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

Targeting Disease Modification in Psoriasis and Psoriatic Arthritis

Experts conclude the series discussing how to approach switching psoriasis treatments.

When to Switch a Drug Class in Psoriasis Treatment

Dermatologists discuss their approach to managing patients who have experienced treatment failure. They debate whether to switch to a different class of drug or remain within the same class based on factors such as primary versus secondary failure and individual patient response. They also mention specific drugs within the class, like bimekizumab, and discuss the efficacy and considerations of different options. The conversation highlights the complexity of decision-making in dermatology regarding treatment selection for patients who have not responded to TNF blockers.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Experts discuss package warnings associated with bimekizumab and how they inform patients of them.

Warnings and Precautions for Newer Psoriasis Treatments

Regarding the warnings in the bimekizumab package insert, specifically about suicidal ideation and elevated liver enzymes, different approaches are taken by physicians in discussing these potential side effects with patients, but each aim to address those concerns with their patients.

Regarding suicidal ideation, some physicians proactively address it with patients, discussing the very rare occurrence of suicidal behavior observed in clinical trials in order for complete transparency. They may reassure patients that no causal association has been established and encourage open communication if any changes in mood or symptoms are noticed. Others may not explicitly mention this warning but address the broader impact of psoriasis on mental health, even directly asking patients about their mental wellbeing, and encouraging patients to report any concerns.

Concerning elevated liver enzymes, physicians acknowledge the recommendation for monitoring but may customize the frequency based on individual patient factors such as comorbidities and suspicion of liver disease. They emphasize the need for initial screening before treatment initiation and potentially more frequent monitoring in high-risk patients. Despite the warning, physicians highlight that elevations in liver enzymes are typically mild and manageable, often related to factors such as fatty liver or alcohol consumption.

Saakshi Khattri, MD

Articles